IPA to Report Second Quarter Fiscal 2023 Financial Results and Near-Term Business Highlights on December 15, 2022

Company to Host Earnings Conference Call Via Webcast

Victoria, British Columbia, December 5, 2022–(BUSINESS WIRE)–IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA), today announced that it will hold a conference call to discuss Its quarterly results and near-term business highlights for the second quarter of fiscal 2023, Thursday, December 15, 2022 at 10:30 am ET. Financial results will be released in a press release prior to the conference call.

ImmunoPrecise management will host the conference call, followed by a question-and-answer session.

telephone conference:

Date: Thursday, December 15, 2022
Time: 10:30 a.m. ET

Participant Information:

Conference number: 9236374
Participant toll-free dial-in number: 1 (888) 550-5658
Participant Fee Dial-in Number: 1 (646) 960-0289

Attendee URL: https://events.q4inc.com/attendee/662019205

The conference call will be webcast live and a replay is available via a link provided in the Events section of the company’s IR page at https://www.immunoprecise.com/investors.

Please dial the conference call five minutes before the start time. The operator will register your name and organization.

Anyone listening to the conference call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and the Securities and Exchange Commission, including the discussion of risk factors, historical operating performance and financial condition contained in those reports.

ImmunoPrecise Antibody Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe, including entities such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively the “IPA family”). IPA Family is a biotherapeutics research and technology group that leverages systems biology, multi-omics modeling and sophisticated artificial intelligence systems to support its proprietary technology for biological platform-based antibody discovery. Services include a highly specialized, full continuum of therapeutic biologics discovery, development and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. For more information, visit www.ipathrapeutics.com.

View source releases on businesswire.com: https://www.businesswire.com/news/home/20221205005242/en/

contact person

Investor Contact: investors@immunoprecise.com

Source link